Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.
BACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rhe...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3917867?pdf=render |
id |
doaj-67569d3822fc4adc953cd25bd7cd3666 |
---|---|
record_format |
Article |
spelling |
doaj-67569d3822fc4adc953cd25bd7cd36662020-11-24T21:50:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8817710.1371/journal.pone.0088177Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.Gunter AssmannKlara ShihadehViola PoeschelNiels MurawskiJutta ConigliarouMei Fang OngMichael PfreundschuhBACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value <0.05 was statistically significant. RESULTS: ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. CONCLUSIONS: DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls.http://europepmc.org/articles/PMC3917867?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gunter Assmann Klara Shihadeh Viola Poeschel Niels Murawski Jutta Conigliarou Mei Fang Ong Michael Pfreundschuh |
spellingShingle |
Gunter Assmann Klara Shihadeh Viola Poeschel Niels Murawski Jutta Conigliarou Mei Fang Ong Michael Pfreundschuh Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. PLoS ONE |
author_facet |
Gunter Assmann Klara Shihadeh Viola Poeschel Niels Murawski Jutta Conigliarou Mei Fang Ong Michael Pfreundschuh |
author_sort |
Gunter Assmann |
title |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. |
title_short |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. |
title_full |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. |
title_fullStr |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. |
title_full_unstemmed |
Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. |
title_sort |
prevalence of anti-citrullinated protein antibodies (acpa) in patients with diffuse large b-cell lymphoma (dlbcl): a case-control study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
BACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF. ACPA-positive data were stratified into subgroups of RF positivity and established prognostic parameters for DLBCL, including overall survival. In addition, the ACPA serum concentrations levels were compared to an ACPA-positive RA cohort (n = 175). The statistics were performed with χ2 test and Mann- Whitney-U test; Kaplan-Meyer curves (log rank test) were used to analyse the overall survival. P-value <0.05 was statistically significant. RESULTS: ACPA, but not RF, occurred significantly more frequently in the sera of DLBCL patients than in healthy controls (3.5% versus 0.8%, p = 0.030). However, the ACPA serum concentration levels were significantly lower than in RA patients (median 10.4 versus 124.1 U/ml, p = 0.0001). After subgroup stratification, ACPA positivity in DLBCL was significantly associated with male gender (4.4% versus 0%, p = 0.022; odds ratio 1.046, CI 1.014-1.079) and with RF-IgM seropositivity (1.77% versus 0%, p = 0.043), but not with prognostic parameters for DLBCL. CONCLUSIONS: DLBCL is associated with a significantly higher prevalence of ACPA, with an increased prevalence in male patients, and simultaneous RF-IgM positivity. However, ACPA is not prognostic for DLBCL. The prevalence of RF-IgM, -IgA, or -IgG did not differ from healthy controls. |
url |
http://europepmc.org/articles/PMC3917867?pdf=render |
work_keys_str_mv |
AT gunterassmann prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT klarashihadeh prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT violapoeschel prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT nielsmurawski prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT juttaconigliarou prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT meifangong prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy AT michaelpfreundschuh prevalenceofanticitrullinatedproteinantibodiesacpainpatientswithdiffuselargebcelllymphomadlbclacasecontrolstudy |
_version_ |
1725885182789025792 |